Clinical trial
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas…
NCT00424554 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00424554 |
|---|---|
| Title | Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) |
| Official title | A Phase II Trial to Evaluate the Effect of Low Dose Temozolomide (TMZ) for 2 Weeks on Brain Tumor O-6-methylguanine-DNA Methyltransferase (MGMT) Activity in Patients With Gliomas. |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioma |
| Intervention type | Drug |
| Interventions | temozolomide |
| Enrollment | 40 |
| Start date | Sep 26, 2006 |
| Primary completion | Jan 11, 2010 |
| Completion | Feb 16, 2011 |
| First posted | Jan 19, 2007 |
| Last update posted | Jun 7, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: